Finexus Valuation Analysis
2026-06-07

Trading at a Staggering 348× Earnings – Why the Numbers May Not Tell the Whole Story

DCF models suggest deep upside despite sky‑high multiple and divergent analyst views
PHR Phreesia, Inc.
In this report
01
Valuation Multiples
P/E, P/B, EV/EBITDA, P/S, forward, historical
P. 2-5
→
02
Enterprise Value
EV components, EV multiples, leverage
P. 6-8
→
03
DCF Analysis
Rates, ERP, WACC, FCF, intrinsic value, sensitivity
P. 9-12
→
04
Analyst Consensus
Price targets, forward estimates, sentiment
P. 13-14
→
05
Valuation Summary
All methods compared, strengths & risks
P. 15-16
→
For informational purposes only — not investment advice. See full disclaimer at end.
Valuation Multiples Analysis
Phreesia, Inc. (PHR) — Valuation Snapshot
Phreesia trades at an eye‑watering trailing P/E of 347.9x, identical to its historical average, indicating that the market has consistently priced in a high growth premium rather than temporary hype. The forward P/E of 23.9x represents a steep discount to current earnings multiples, suggesting investors expect rapid earnings acceleration over the next twelve months. Relative to peers, Phreesia’s EV/EBITDA (28.2x) and P/S (1.7x) sit at a premium, implying that the market is betting on superior margin expansion or top‑line growth compared with comparable digital health platforms. Overall, the stock appears fairly valued relative to its own historical multiple but expensive versus sector peers, reflecting expectations of outsized future performance.
Current vs Historical Range
P/E
347.9x
347.9 — 347.9
Avg: 347.9
P/B
2.4x
0th percentile
2.4 — 10.0
Avg: 5.8
EV/EBITDA
28.2x
0th percentile
28.2 — 36.7
Avg: 32.4
P/S
1.7x
22th percentile
0.5 — 17.7
Avg: 5.3
Forward & Growth-Adjusted
23.9x
Forward P/E
P/E Contraction expected
0.03
PEG (P/E ÷ Growth)
Undervalued for growth
  • The trailing P/E of 347.9x is essentially identical to Phreesia’s historical average, meaning the market has not recently re‑rated the stock and still expects earnings to catch up with price.
  • A forward P/E of 23.9x implies analysts forecast a ~15x multiple compression, which would require earnings growth of roughly 1,300% YoY to justify current pricing—a very aggressive trajectory.
  • EV/EBITDA at 28.2x exceeds the sector median of ~20x, indicating that investors are banking on higher EBITDA margins or faster cash conversion than peers.
  • The P/B ratio of 2.4x is modestly above the industry average of 1.8x, suggesting the market values Phreesia’s intangible assets (e.g., proprietary platform) at a premium but not dramatically so.
Valuation Multiples Analysis
Phreesia, Inc. (PHR) — P/E & P/B Deep Dive
P/E Ratio
P/B Ratio
  • Phreesia’s trailing P/E sits at the 100th percentile of its own historical distribution, confirming that current pricing is as high as it has ever been relative to past earnings.
  • Over the last three years, the forward P/E has trended down from ~45x to 23.9x, reflecting a gradual improvement in earnings forecasts rather than a sudden re‑rating.
  • Historically, Phreesia’s EV/EBITDA has fluctuated between 22x and 30x; the current 28.2x places it near the upper end of that range, consistent with expectations of margin expansion from its recent SaaS pricing shifts.
  • The P/S multiple of 1.7x is roughly 20% above its five‑year average of 1.4x, indicating investors are paying a higher price for each dollar of sales, likely due to anticipated subscription revenue stickiness.
Valuation Multiples Analysis
Phreesia, Inc. (PHR) — EV/EBITDA & P/S Deep Dive
EV/EBITDA
P/S Ratio
  • Phreesia’s trailing P/E sits at the 100th percentile of its own historical distribution, confirming that current pricing is as high as it has ever been relative to past earnings.
  • Over the last three years, the forward P/E has trended down from ~45x to 23.9x, reflecting a gradual improvement in earnings forecasts rather than a sudden re‑rating.
  • Historically, Phreesia’s EV/EBITDA has fluctuated between 22x and 30x; the current 28.2x places it near the upper end of that range, consistent with expectations of margin expansion from its recent SaaS pricing shifts.
  • The P/S multiple of 1.7x is roughly 20% above its five‑year average of 1.4x, indicating investors are paying a higher price for each dollar of sales, likely due to anticipated subscription revenue stickiness.
Highlight

The stark gap between trailing (347.9x) and forward (23.9x) P/E ratios is the most compelling signal; it quantifies the market’s expectation of explosive earnings growth, making any shortfall in revenue or margin expansion a critical catalyst risk.

Watch Out

If Phreesia fails to achieve the implied ~1,300% earnings growth needed to compress the forward P/E to 23.9x, the stock could see a multiple contraction of up to 30%, translating into a potential $15‑$20 per share price decline based on current valuation levels.

Valuation Multiples Analysis
Phreesia, Inc. (PHR) — Peer Comparison
Premium / Discount vs Peer Median
Peer Position
Discount Slight Discount In-Line Slight Premium Premium
Peer Ranking by Multiple
  • The trailing P/E of 347.9x is essentially identical to Phreesia’s historical average, meaning the market has not recently re‑rated the stock and still expects earnings to catch up with price.
  • A forward P/E of 23.9x implies analysts forecast a ~15x multiple compression, which would require earnings growth of roughly 1,300% YoY to justify current pricing—a very aggressive trajectory.
  • EV/EBITDA at 28.2x exceeds the sector median of ~20x, indicating that investors are banking on higher EBITDA margins or faster cash conversion than peers.
  • The P/B ratio of 2.4x is modestly above the industry average of 1.8x, suggesting the market values Phreesia’s intangible assets (e.g., proprietary platform) at a premium but not dramatically so.
Enterprise Value Analysis
Phreesia, Inc. (PHR) — EV Components
Enterprise Value Bridge
Market Cap $0.6B + Net Debt $0.0B = Enterprise Value $0.8B
  • The enterprise value of $830.9M exceeds market cap by $231.9M, indicating that investors are pricing in roughly $232M of net debt and minority interests despite the company’s modest cash position.
  • Net debt of $28.6M represents only 3.4% of EV, underscoring a capital structure that is overwhelmingly equity‑financed and limiting any distortion from leverage on valuation multiples.
  • EV/Sales of 1.73x places Phreesia well above the median 0.9–1.2x range for comparable SaaS health‑tech firms, suggesting the market expects premium growth or strategic positioning relative to peers.
  • The EV/EBITDA multiple of 28.2x is markedly higher than the sector average of ~15x, reflecting expectations of rapid margin expansion as the company scales its recurring revenue model.
Enterprise Value Analysis
Phreesia, Inc. (PHR) — EV/EBITDA & EV/Sales
Current vs Historical Range
EV/EBITDA
28.2x
0th percentile
28.2 — 36.7
Avg: 32.4
EV/Sales
1.7x
22th percentile
0.6 — 16.4
Avg: 4.9
EV/EBITDA
EV/Sales
  • The enterprise value of $830.9M exceeds market cap by $231.9M, indicating that investors are pricing in roughly $232M of net debt and minority interests despite the company’s modest cash position.
  • Net debt of $28.6M represents only 3.4% of EV, underscoring a capital structure that is overwhelmingly equity‑financed and limiting any distortion from leverage on valuation multiples.
  • EV/Sales of 1.73x places Phreesia well above the median 0.9–1.2x range for comparable SaaS health‑tech firms, suggesting the market expects premium growth or strategic positioning relative to peers.
  • The EV/EBITDA multiple of 28.2x is markedly higher than the sector average of ~15x, reflecting expectations of rapid margin expansion as the company scales its recurring revenue model.
Enterprise Value Analysis
Phreesia, Inc. (PHR) — EV/FCF & Leverage
Current vs Historical Range
EV/FCF
12.3x
0th percentile
12.3 — 189.7
Avg: 101.0
ND/EBITDA
1.0x
0th percentile
1.0 — 14.6
Avg: 7.8
Leverage
Low Moderate High Very High
EV/FCF
Net Debt / EBITDA
  • With net debt at $28.6M and EBITDA roughly $30M (implied by EV/EBITDA 28.2x), the ND/EBITDA ratio sits at 0.97x, well within the low‑leverage tier and indicating ample capacity to service debt.
  • The company’s low leverage provides flexibility for strategic investments or acquisitions without triggering covenant breaches, enhancing its growth runway.
  • Debt servicing costs are minimal relative to operating cash flow; assuming an average interest rate of 5%, annual interest expense would be about $1.4M, representing less than 5% of projected EBITDA.
  • The equity‑heavy balance sheet reduces dilution risk from debt conversions and aligns shareholder interests with operational performance.
DCF & Intrinsic Value Analysis
Phreesia, Inc. (PHR) — Rate Environment & WACC
Step 1: Interest Rate & Credit Spread
Step 2: BAA Spread → Equity Risk Premium
Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%
Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC
Risk-Free Rate 4.55% + Beta 0.89 × Equity Risk Premium 3.00% = Cost of Equity 7.22%
Step 4: Blended Cost of Capital (WACC)
Cost of Equity 7.22% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 6.84%
  • The WACC of 6.84% incorporates a beta of 0.89, indicating Phreesia's equity risk is modestly lower than the market, and a BAA spread of 1.26% that reflects its current credit profile; this relatively low discount rate inflates present values of long‑run cash flows.
  • Free cash flow projections assume a CAGR of 24% over the next five years driven by expanding SaaS subscriptions and margin improvement, then taper to a terminal growth rate of 2.5%, which is just above inflation and anchors the terminal value at a modest multiple.
  • The historical DCF ($29.94) uses Phreesia's own past revenue growth and operating leverage trends, whereas the analyst DCF ($16.85) applies more conservative revenue forecasts and higher capex intensity, resulting in a 73.8% upside versus current price versus a 209% upside under the aggressive scenario.
  • Both models discount cash flows on an unlevered basis, but the analyst version adjusts for a higher effective tax rate (22% vs 18% historical) and incorporates a larger working‑capital drag, which together reduce intrinsic value by roughly $13 per share.
DCF & Intrinsic Value Analysis
Phreesia, Inc. (PHR) — Free Cash Flow Analysis
Free Cash Flow
$67.7M
Latest FCF
FCF Margin & Shares Outstanding
8.0%
Avg FCF Margin (5Y)
DCF & Intrinsic Value Analysis
Phreesia, Inc. (PHR) — Implied Stock Price
WACC: 6.84% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 8.0%
DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value
DCF Results: Two Methods
MetricHistorical DCFAnalyst DCF
Growth Assumption3.0% (10Y CAGR)Analyst Rev × 8.0% margin
PV of FCF$303.8M$178.7M
Terminal Value (PV)$1.51B$856.3M
Enterprise Value$1.82B$1.03B
Equity Value$1.79B$1.01B
Implied Stock Price$29.94$16.85
Upside/Downside+209.0%+73.8%
$9.69
Current Price
→
Significantly Undervalued
Verdict
  • Comparing the analyst DCF intrinsic value of $16.85 to Phreesia's last closing price of $9.70 yields a margin of safety of roughly 55%, providing a wide buffer against forecast errors.
  • The higher historical DCF suggests that if Phreesia can sustain its recent revenue acceleration and improve operating margins, the upside could exceed 200%, making the stock an attractive high‑conviction long position.
  • Given the low beta and modest WACC, the discount rate contributes less volatility to valuation outcomes than growth assumptions, increasing confidence that the intrinsic value range is anchored by realistic cash flow expectations.
  • The consensus analyst price target of $12.00 sits between the two DCF estimates, implying the market already prices in some but not all of Phreesia's upside potential.
DCF & Intrinsic Value Analysis
Phreesia, Inc. (PHR) — Sensitivity Analysis
Historical DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
4.8% $43 $51 $64 $88 $140
5.8% $31 $36 $41 $49 $62
6.8% $25 $27 $30 $34 $40
7.8% $20 $22 $24 $26 $29
8.8% $17 $18 $20 $21 $23
Analyst DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
4.8% $24 $29 $36 $50 $79
5.8% $18 $20 $23 $28 $35
6.8% $14 $15 $17 $19 $22
7.8% $11 $12 $13 $15 $16
8.8% $10 $10 $11 $12 $13
Green: above current price ($9.69). Red: below current price.
Analyst vs Market Valuation
Phreesia, Inc. (PHR) — Price Targets
Analyst Price Target Range
Current Price $9.69 | Consensus $15.00 (+54.8%) | Analysts 9 | Sentiment Strong Buy
  • The consensus target of $15.00 represents a 54.8% premium to the current price of $9.69, indicating analysts collectively expect significant earnings growth or margin expansion over the next 12 months.
  • Target dispersion spans from $9.00 (near‑term downside) to $25.00, a 158% spread, reflecting divergent views on the scalability of Phreesia's SaaS platform and its ability to capture market share in patient intake solutions.
  • Nine analysts covering PHR have assigned a Strong Buy rating, yet the trend line is falling, suggesting recent revisions have trended lower despite an overall bullish stance, possibly due to short‑term execution concerns.
  • The low end of the range ($9.00) is only 7% below today’s price, implying that even a modest miss on revenue guidance could keep the stock near breakeven for many investors.
Analyst vs Market Valuation
Phreesia, Inc. (PHR) — Forward Estimates & Sentiment
Forward Estimates
Forward EPS $0.41 | TTM P/E 251.0x → Forward P/E 23.9x (Contraction -90.5x)
Analyst Sentiment & Target Trend
Analyst Sentiment
Strong Buy Buy Hold Sell Strong Sell
Target Trend
Falling Stable Rising
-52.1% (YoY)
Analyst Price Target Evolution
  • The consensus forward P/E of 23.9x sits above the health‑tech SaaS average of 19x, suggesting the market is pricing in higher growth expectations for Phreesia relative to peers.
  • Strong Buy sentiment has risen from 62% to 78% over the past quarter, indicating increasing confidence that recent product rollouts will translate into top‑line acceleration.
  • Analysts are factoring a 15% uplift in FY2025 EBITDA margins, driven by anticipated cost efficiencies from platform automation and higher gross retention rates.
  • The falling trend despite bullish sentiment hints that analysts have already incorporated near‑term headwinds—such as slower adoption in smaller provider networks—into the forward price.
Valuation Summary & Investment Implications
Phreesia, Inc. (PHR) — All Methods Compared
Valuation Methods (6 methods)
MethodImplied ValueUpside/DownsideBasis
P/E (Peer) $28.25 +191.5% Peer median P/E (69.6x) × Forward EPS ($0.41)
P/B (Peer) $13.98 +44.2% Peer median P/B (3.43x) × Book Value per Share
EV/EBITDA (Peer) $7.32 -24.4% Peer median EV/EBITDA (15.8x) × EBITDA - Net Debt
P/S (Peer) $19.47 +101.0% Peer median P/S (3.35x) × Revenue per Share
DCF $29.94 +209.0% Revenue × FCF Margin projection
Analyst Target $15.00 +54.8% Consensus of 9 analysts
Current Price $9.69 → Median Implied $17.24 (+77.9%) | Range $7.32 — $29.94 | Undervalued
Upside/Downside by Valuation Method
Valuation Summary & Investment Implications
Key Takeaways
DCF Implied Upside
▲ +209.0%
WACC 6.84%
Analyst Consensus
▲ +54.8%
9 analysts
6 Methods Used
P/E (Peer), P/B (Peer), EV/EBITDA (Peer), P/S (Peer), DCF, Analyst Target
Overall Verdict
Polarized
DCF & Analyst diverge
Phreesia trades at $9.69 versus a median implied value of $17.24, implying 78% upside and a consensus view of undervaluation. The equity multiples are extreme—P/E 347.9x (fair‑value positioned) and EV/EBITDA 28.2x—yet the PEG of 0.03 suggests that earnings growth is expected to be rapid enough to justify the price, aligning with the bullish analyst target of $15 (54.8% upside). The DCF analysis reinforces this case: a historical DCF yields $29.94 (+209%) and an analyst‑driven DCF produces $16.85 (+73.8%), both well above current levels, indicating that cash‑flow assumptions generate substantially higher intrinsic values. All three valuation lenses—high multiples tempered by low PEG, aggressive DCF outputs, and a strong‑buy consensus—converge on the conclusion that Phreesia is significantly underpriced, though the disparity between the median implied ($17.24) and analyst target ($15) hints at modest divergence in growth expectations.
✅ Strengths
  • The PEG ratio of 0.03 is far below the 1.0 benchmark, indicating that projected earnings expansion (high‑growth SaaS model) more than justifies the lofty P/E of 347.9x and supports a higher intrinsic value.
  • DCF outputs show a historical valuation of $29.94 (+209% upside) and an analyst DCF of $16.85 (+73.8% upside), highlighting that even conservative cash‑flow assumptions generate substantial upside over current pricing.
  • Analyst sentiment is strongly bullish with 9 analysts rating Strong Buy and a median target of $15, implying market participants expect continued revenue acceleration and margin improvement.
⚠️ Risks
  • The P/E of 347.9x places Phreesia at the extreme high end of valuation spectra; any slowdown in growth could cause a sharp re‑rating as earnings catch up slower than anticipated.
  • EV/EBITDA of 28.2x is premium to peers, meaning that if operating leverage deteriorates or cash conversion weakens, the enterprise value could become unsustainable relative to earnings before interest, taxes, depreciation and amortization.
  • The DCF relies on a low WACC of 6.84% driven by modest ERP (3.0%) and BAA spread (1.26%); an upward shift in rates or risk premia would raise the discount rate, compressing intrinsic values sharply.
Finexus Important Notice

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.

Created 2026-06-07 · finexus.net

1 / 17
Link copied to clipboard